CDR-Life, a clinical-stage biotechnology company, is naming Dimitrios Chondros, MD, its new Chief Medical Officer (CMO). In that post, Chondros will oversee clinical development, clinical operations, medical affairs, and translational strategy.

CDR-Life Makes Strides in Oncology

As this relates to CDR-Life, the company develops highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases. The company’s first oncology program is now in clinical trials.

Currently, CDR-Life is continuing translation of its proprietary M-gager platform into clinical-stage programs. To further define M-gager, CDR-Life says the platform delivers TCEs against challenging yet clean targets with proficient binding specificity.

In November 2025, CDR-Life’s long-standing partnership with Boehringer Ingelheim was expanded concerning one of these M-gagers. At that time, the companies announced a new, global licensing agreement to develop the trispecific M-gager CDR111. Under the terms of the agreement, CDR-Life is eligible for up to $570 million in payments for the antibody-based molecule.

According to the announcement of Chondros’ appointment, that candidate has now progressed to Phase II in the clinic.

“CDR-Life’s M-gager platform represents a compelling evolution in multispecific T cell engagers, combining precision, potency and developability,” Chondros said. “I look forward to working with the team to translate this differentiated science into meaningful clinical outcomes for patients.”

Chondros Brings Experience to CMO Post

Prior to his CDR-Life Appointment, Chondros, a board-certified general surgeon, was CMO at Halozyme. He was also previously Global Development Team Leader at Genentech, for that company’s colorectal cancer treatment Avastin (bevacizumab).

CDR-Life CEO Christian Leisner, PhD, called Chondros “highly respected,” combining “hands-on drug development experience, global leadership perspective, and medical expertise.”

Leisner said those elements are important as CDR-Life continues to progress its M-gager programs in the clinic.

“Dimitrios’ leadership will be instrumental in guiding our clinical strategy and execution,” Leisner said.